bpi-1178
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 15, 2020 (NCT04282031)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Cyclin-dependent kinase 6INHIBITOR
CDK6 inhibitor
- Cyclin-dependent kinase 4INHIBITOR
CDK4 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06362980 | Phase 1 | May 22, 2024 | Government of China, National Cancer Center, China |
| NCT04282031 | Phase 1/Phase 2 (Phase 2) | Mar 15, 2020 | Beta Pharma, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Beta Pharma, Inc. | For profit | 1 | 1 | 1 | 2020 |
| Government of China | Government | 1 | 0 | 1 | 2024 |
| National Cancer Center, China | Academic/Hospital | 1 | 1 | 1 | 2024 |
3 organizations
Page 1 / 1